Similar articles

• [Chronic hepatitis C--therapeutic modalities for interferon failure].

  Hermann R. Hermann R. Praxis (Bern 1994). 1998 Oct 14;87(42):1413-20. Praxis (Bern 1994). 1998. PMID: 9824949 Review. German.
• Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C.

  Roehr B. Roehr B. J Int Assoc Physicians AIDS Care. 1998 Jul;4(7):24-9. J Int Assoc Physicians AIDS Care. 1998. PMID: 11365638
• Evaluation of amantadine in chronic hepatitis C: a meta-analysis.

  Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, De Maeght S, Paris JC, Mathurin P. Deltenre P, et al. J Hepatol. 2004 Sep;41(3):462-73. doi: 10.1016/j.jhep.2004.05.019. J Hepatol. 2004. PMID: 15336450
• [Ribavirin/interferon-alpha combination in treatment of chronic hepatitis C: what is the status today?].

  Renner EL. Renner EL. Schweiz Med Wochenschr. 1999 Jan 12;129(1-2):8-10. Schweiz Med Wochenschr. 1999. PMID: 10065494 Review. German. No abstract available.
• [Hepatitis C: therapeutic perspectives].

  Trépo C. Trépo C. Gastroenterol Clin Biol. 2002 Apr;26 Spec No 2:B297-302. Gastroenterol Clin Biol. 2002. PMID: 12180304 Review. French. No abstract available.